FDA approves Zynyz for advanced anal cancer, marking a breakthrough for the 10,000 diagnosed annually—including actress ...

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer and the fourth leading cause of cancer-related death, has a 5-year survival rate of less than 10%.1 The impact of pancreatic ...

Dedicated to the future of cancer treatment, this topic covers emerging targeted and immunotherapeutic approaches in solid tumors and hematologic ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

Despite groundbreaking advances in pediatric cancer research, many promising therapies never reach the children who need them most. Catherine Bollard, MD, is senior vice president and chief research ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco ...

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...